Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | FAP | Q12884 | 10/20 | 0.67 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Denagliptin SCHEMBL2552817 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL987759 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL18815071 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL1035624 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL3151455 | 0.99 | DPP4 (0.98) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL13986697 | 0.94 | DPP4 (0.89) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5549926 | 0.89 | DPP4 (0.80) | DPP4FAPDPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL3157260 | 0.88 | DPP4 (0.79) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL4801510 | 0.87 | DPP4 (0.76) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12350113 | 0.87 | DPP4 (0.77) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4686474-A1 | DPP-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE LIVER DISEASES | Delta 4 GmbH (AT) | 2026-02-04 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025057088-A1 | RNA COMPOSITIONS FOR DELIVERY OF INCRETIN AGENTS | BioNTech SE (DE) | 2025-03-20 | — | — | WO | claimed |
| EP-3804715-B1 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION COMPRISING GLUCOKINASE ACTIVATOR AND DPP-IV INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | HUA MEDICINE SHANGHAI LTD (CN) | 2024-12-25 | — | — | EP | claimed |
| US-20240299357-A1 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION COMPRISING GLUCOKINASE ACTIVATOR AND DPP-IV INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | HUA MEDICINE (SHANGHAI) LIMITED (CN) | 2024-09-12 | — | — | US | claimed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| US-20240100048-A1 | DIPEPTIDYLPEPTIDASE 4 INHIBITION ENHANCES LYMPHOCYTE TRAFFICKING, IMPROVING BOTH NATURALLY OCCURRING TUMOR IMMUNITY AND IMMUNOTHERAPY | INSTITUT PASTEUR (FR) | 2024-03-28 | — | — | US | claimed |
| US-11883398-B2 | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy | INSTITUT PASTEUR (FR) | 2024-01-30 | — | — | US | claimed |
| WO-2024015889-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-18 | — | — | WO | claimed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | claimed |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | claimed |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | claimed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | claimed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| EP-1654226-B1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1406873-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-09-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299357-A1 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION COMPRISING GLUCOKINASE ACTIVATOR AND DPP-IV INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | DPP4, DPP7, DPP8 | DPP4 1/4885FAP 91/4885DPP8 3/4885 |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 365/4885DPP8 15/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | DPP4 10/4885FAP 882/4885DPP8 41/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885FAP 850/4885DPP8 8/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 366/4885DPP8 10/4885 |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 416/4885DPP8 11/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | DPP4 6/4885FAP 939/4885DPP8 28/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | DPP4 9/4885FAP 799/4885DPP8 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.